Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;35(Suppl 1):21-31.
doi: 10.1007/s40273-017-0545-x.

A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models

Affiliations
Free article
Review

A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models

John Brazier et al. Pharmacoeconomics. 2017 Dec.
Free article

Abstract

Generic preference-based measures (GPBMs) of health are used to obtain the quality adjustment weight required to calculate the quality-adjusted life year in health economic models. GPBMs have been developed to use across different interventions and medical conditions and typically consist of a self-complete patient questionnaire, a health state classification system, and preference weights for all states defined by the classification system. Of the six main GPBMs, the three most frequently used are the Health Utilities Index version 3, the EuroQol 5 dimensions (3 and 5 levels), and the Short Form 6 dimensions. There are considerable differences in GPBMs in terms of the content and size of descriptive systems (i.e. the numbers of dimensions of health and levels of severity within these), the methods of valuation [e.g. time trade-off (TTO), standard gamble (SG)], and the populations (e.g. general population, patients) used to value the health states within the descriptive systems. Although GPBMs are anchored at 1 (full health) and 0 (dead), they produce different health state utility values when completed by the same patient. Considerations when selecting a measure for use in a clinical trial include practicality, reliability, validity and responsiveness. Requirements of reimbursement agencies may impose additional restrictions on suitable measures for use in economic evaluations, such as the valuation technique (TTO, SG) or the source of values (general public vs. patients).

PubMed Disclaimer

References

    1. Pharmacoeconomics. 2017 Dec;35(Suppl 1):11-19 - PubMed
    1. Soc Sci Med. 2014 Aug;114:38-48 - PubMed
    1. Health Technol Assess. 2014 Feb;18(9):1-224 - PubMed
    1. Health Econ. 2014 Jun;23(6):729-42 - PubMed
    1. Appl Health Econ Health Policy. 2004;3(2):103-5 - PubMed

LinkOut - more resources